Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
So Kyowa Kirin just took back full control of rocatinlimab from Amgen. Interesting move - Amgen's doing a portfolio review and apparently this atopic dermatitis drug didn't make the cut for them, but the Japanese company clearly still believes in it.
The Phase 3 data from late last year actually looked solid. Both ROCKET-IGNITE and ROCKET-HORIZON hit their marks, and the extension study showed the drug could work with extended dosing intervals. That's usually a good sign for commercialization - less frequent dosing tends to help adoption rates for dermatitis treatments.
What caught my attention is the OX40 receptor angle. There's definitely differentiation there compared to other approaches in the atopic dermatitis space. Kyowa Kirin's betting this mechanism will resonate with patients dealing with moderate-to-severe cases.
Amgen staying on as manufacturer is smart - keeps things stable while Kyowa pushes forward solo. Curious to see how they handle the regulatory path for dermatitis approval now that they've got the full reins. Not everyone can pull off what Amgen couldn't.